Why Acadia Pharmaceuticals Stock Is Soaring Today

Acadia Pharmaceuticals shares surged 12.2% after the European Medicines Agency's Committee recommended approval of Daybue for Rett syndrome treatment in the EU. The company, which focuses on rare neurological and psychiatric disorders, is profitable with two approved drugs generating significant revenue. While the European market for Rett syndrome may be modest, Acadia faces minimal competition in its niche.